Design, synthesis and biological evaluation of l-dopa amide derivatives as potential prodrugs for the treatment of Parkinson's disease

European Journal of Medicinal Chemistry

Volumn 45, Issue 9, 2010, Pages 4035-4042

  Zhou, Tao ^a,b   Hider, Robert C ^b   Jenner, Peter ^b   Campbell, Bruce ^b   Hobbs, Christopher J ^b   Rose, Sarah ^b   Jairaj, Mark ^b   Tayarani Binazir, Kayhan A ^b   Syme, Alexander ^b  

^a ZHEJIANG GONGSHANG UNIVERSITY   (China)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

6 hydroxydopamine (6 OHDA) lesioned rat; Dopamide; l dopa; Parkinson's disease; Prodrug

Indexed keywords

1 AMINO 3 (3,4 DIACETOXYPHENYL) 1 OXOPROPAN 2 AMMONIUM CHLORIDE; 1 AMINO 3 (3,4 DIHYDROXYPHENYL) 1 OXOPROPAN 2 AMMONIUM CHLORIDE; 3 (3,4 DIACETOXYPHENYL) 1 (DIMETHYLAMINO) 1 OXOPROPAN 2 AMMONIUM CHLORIDE; 3 (3,4 DIACETOXYPHENYL) 1 (ETHYLAMINO) 1 OXOPROPAN 2 AMMONIUM CHLORIDE; 3 (3,4 DIACETOXYPHENYL) 1 (ISOPROPYLAMINO) 1 OXOPROPAN 2 AMMONIUM CHLORIDE; 3 (3,4 DIACETOXYPHENYL) 1 (METHYLAMINO) 1 OXOPROPAN 2 AMMONIUM CHLORIDE; 3 (3,4 DIHYDROXYPHENYL) 1 (ETHYLAMINO) 1 OXOPROPAN 2 AMMONIUM CHLORIDE; 3 (3,4 DIHYDROXYPHENYL) 1 (METHYLAMINO) 1 OXOPROPAN 2 AMMONIUM CHLORIDE; 3 (3,4 DIHYDROXYPHENYL) 1 (PHENETHYLAMINO) 1 OXO PROPAN 2 AMMONIUM CHLORIDE; 3 [3,4 BIS(ETHOXYCARBONYLOXY)PHENYL] 1 AMINO 1 OXOPROPAN 2 AMMONIUM CHLORIDE; AMIDE; ANTIPARKINSON AGENT; LEVO DOPAMIDE DERIVATIVE; LEVODOPA; OXIDOPAMINE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BRAIN DAMAGE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; EXPERIMENTAL MODEL; GEL CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; RAT; TANDEM MASS SPECTROMETRY;

AMIDES; ANIMALS; DRUG DESIGN; LEVODOPA; MALE; OXIDOPAMINE; PARKINSON DISEASE; PRODRUGS; RATS; RATS, WISTAR;

EID: 77955557474     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2010.05.062     Document Type: Article

References (18)

1. P.A. Serra, G. Esposito, P. Enrico, M.A. Mura, R. Migheli, and M.R. Delogu Br. J. Pharmacol. 130 2000 937 945
2. G.K. Tofaris, and M.G. Spillantini Mov. Disord. 20 2005 S37 44
3. J. Weber, and G.M. Keating CNS Drugs 23 2009 81 89
4. A. Antonini, and P. Barone Neurol. Sci. 29 2008 S371 S374
5. H.P. Wang, J.S. Lee, M.C. Tsai, H.H. Lu, and W.L. Hsu Bioorg. Med. Chem. Lett. 5 1995 2195 2198
6. A. Di Stefano, B. Mosciatti, G.M. Cingolati, G. Giorgioni, M. Riccitutelli, and I. Cacciatore Bioorg. Med. Chem. Lett. 11 2001 1085 1088
7. E. Santini, E. Valjent, and G. Fisone FEBS J. 275 2008 1392 1399
8. A.D. Stefano, P. Sozio, and S.L. Cerasa Molecules 13 2008 46 68
9. F. Pinnen, I. Cacciatore, C. Cornacchia, P. Sozio, A. Iannitelli, and M. Costa J. Med. Chem. 50 2007 2506 2515
10. F. Pinnen, I. Cacciatore, C. Cornacchia, P. Sozio, S.L. Cerasa, and A. Iannitelli J. Med. Chem. 52 2009 559 563
11. D. Atlas, L-Dopa amide derivatives and uses thereof. US2006025385(A1).
12. R.K.W. Schwarting, and J.P. Huston Prog. Neurobiol. 50 1996 275 331
13. M. Ihara, Y. Tsuchiya, Y. Sawasaki, A. Hisaka, H. Takehana, and K. Tomimoto J. Pharm. Sci. 78 1989 525
14. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Adv. Drug Deliver. Rev. 23 1997 3 25
15. http://www.molinspiration.com/cgi-bin/properties
16. U. Ungerstedt Acta Physiol. Scand. 367 Suppl. 1971 69 93
17. F.M. Otis, L. Levesque, F. Marceau, J. Lacroix, and R.C. Gaudreault Inflammopharmacology 1 1992 201 212
18. L.E. Piatnitski-Chekler, A.J. Butera, D. Li, E.R. Swillo, A.G. Morgan, and I.E. Rossman Biorg. Med. Chem. Lett. 19 2009 4551 4554